@article{0e74287c2e114ccb818907f6bdbc798f,
title = "Prior vaccination with rVSV-ZEBOV does not interfere with but improves efficacy of postexposure antibody treatment",
abstract = "A replication-competent vesicular stomatitis virus vaccine expressing the Ebola virus (EBOV) glycoprotein (GP) (rVSV-ZEBOV) was successfully used during the 2013-16 EBOV epidemic. Additionally, chimeric and human monoclonal antibodies (mAb) against the EBOV GP have shown promise in animals and humans when administered therapeutically. Uncertainty exists regarding the efficacy of postexposure antibody treatments in the event of a known exposure of a recent rVSV-ZEBOV vaccinee. Here, we model a worst-case scenario using rhesus monkeys vaccinated or unvaccinated with the rVSV-ZEBOV vaccine. We demonstrate that animals challenged with a uniformly lethal dose of EBOV one day following vaccination, and then treated with the anti-EBOV GP mAb MIL77 starting 3 days postexposure show no evidence of clinical illness and survive challenge. In contrast, animals receiving only vaccination or only mAb-based therapy become ill, with decreased survival compared to animals vaccinated and subsequently treated with MIL77. These results suggest that rVSV-ZEBOV augments immunotherapy.",
author = "Cross, {Robert W.} and Bornholdt, {Zachary A.} and Abhishek Prasad and Geisbert, {Joan B.} and Viktoriya Borisevich and Agans, {Krystle N.} and Deer, {Daniel J.} and Kevin Melody and Karla Fenton and Heinz Feldmann and Armand Sprecher and Larry Zeitlin and Geisbert, {Thomas W.}",
note = "Funding Information: The authors would like to thank the UTMB Animal Resource Center for husbandry support of laboratory animals, Dr. Chad Mire for assistance with the animal studies, and Natalie Dobias for expert histology and immunohistochemistry support. We also thank Drs. Luis Branco and Matt Boisen of Zalgen for generously providing EBOV VP40 antigen-coated plates for the ELISA work. We also thank Dr. Tina Parker for helpful discussions. This study was supported by the Department of Health and Human Services, National Institutes of Health grants U19AI109711 and U19AI142785 to T.W.G. and UC7AI094660 for BSL-4 operations support of the Galveston National Laboratory. Partial funding was provided through the Intramural research program, NIAID/NIH to H.F. Opinions, interpretations, conclusions, and recommendations are those of the authors and are not necessarily endorsed by the University of Texas Medical Branch or the National Institutes of Health. Publisher Copyright: {\textcopyright} 2020, The Author(s).",
year = "2020",
month = dec,
day = "1",
doi = "10.1038/s41467-020-17446-4",
language = "English (US)",
volume = "11",
journal = "Nature communications",
issn = "2041-1723",
publisher = "Nature Publishing Group",
number = "1",
}